NOVAVAX INC Earnings Per Share (Basic)
NOVAVAX INC (NVAX) reported Earnings Per Share (Basic) of -$0.32 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- NOVAVAX INC earnings per share, basic for the quarter ending 2026-06-30 was -$0.32, a 148.48% decline year-over-year.
- NOVAVAX INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.06, a 101.86% decline year-over-year.
- NOVAVAX INC earnings per share, basic for the quarter ending 2025-12-31 was $0.11.
- NOVAVAX INC earnings per share, basic for the quarter ending 2025-09-30 was -$1.25.
- NOVAVAX INC earnings per share, basic for fiscal 2025 was $2.72.
- NOVAVAX INC earnings per share, basic for fiscal 2024 was -$1.23.
- NOVAVAX INC earnings per share, basic for fiscal 2023 was -$5.41.
- NOVAVAX INC earnings per share, basic for fiscal 2022 was -$8.42.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.32 10-Q · filed 2026-08-06 | -$0.38 10-Q · filed 2026-08-06 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.06 10-Q · filed 2026-05-06 | $0.05 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | $0.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.72 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.25 10-Q · filed 2025-11-06 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.61 10-Q · filed 2025-11-06 | $2.12 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | $0.66 10-Q · filed 2026-08-06 | $3.87 10-Q · filed 2026-08-06 | $3.38 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.63 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | $3.22 10-Q · filed 2026-05-06 | $2.72 derived: net income ÷ weighted average shares · filed 2026-05-06 | $1.97 derived: net income ÷ weighted average shares · filed 2026-05-06 | $3.04 derived: net income ÷ weighted average shares · filed 2026-05-06 |
| 2024-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.23 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.76 10-Q · filed 2025-11-06 | $0.27 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.71 10-Q · filed 2025-11-06 | -$1.99 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | $1.09 10-Q · filed 2025-08-06 | $0.10 10-Q · filed 2025-08-06 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$1.05 10-Q · filed 2025-05-08 | -$2.47 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.73 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.49 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.72 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$5.41 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.26 10-Q · filed 2024-11-12 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.94 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.65 10-Q · filed 2024-08-08 | -$2.69 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$3.41 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$8.42 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$2.15 10-Q · filed 2023-11-09 | -$6.13 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$6.53 10-Q · filed 2023-08-08 | -$3.97 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $2.66 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$23.44 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$4.31 10-Q · filed 2022-11-09 | -$12.13 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$4.75 10-Q · filed 2022-08-09 | -$7.82 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$3.05 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$7.27 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$3.21 10-Q · filed 2021-11-05 | -$4.39 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | -$0.30 10-Q · filed 2021-08-05 | -$0.84 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | -$5.51 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |